Home › Trials › NCT07271186

ANGPTL3 inhibition for adults with diabetic kidney disease

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ANGPTL3 Inhibition With Either Small-Interfering RNA Alone or in Combination With an ANGPTL3 Antibody in Participants With Diabetic Kidney Disease

Phase 2 Interventional Regeneron Pharmaceuticals · NCT07271186

This study tests whether two drugs that block ANGPTL3, ALN-ANG3 and evinacumab, are safe and help adults with type 2 diabetes who have diabetic kidney disease.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment270 (estimated)
Ages18 Years to 80 Years
SexAll
SponsorRegeneron Pharmaceuticals Industry-sponsored
Drugs / interventionsevinacumab
Locations47 sites (Huntsville, Alabama and 46 other locations)
Trial IDNCT07271186 on ClinicalTrials.gov

What this trial studies

This Phase 2 interventional trial gives participants ALN-ANG3, evinacumab, or matched placebo and follows them over time for safety, drug levels in the blood, and effects on kidney-related measures such as albuminuria and estimated glomerular filtration rate. Eligible adults have type 2 diabetes with moderate-to-severe albuminuria and an eGFR between 30 and 90 mL/min/1.73 m2. The study monitors side effects, pharmacokinetics, and exploratory efficacy signals to inform further development. Results will help determine whether ANGPTL3 inhibition merits larger trials in diabetic kidney disease.

Who should consider this trial

Good fit: Adults with type 2 diabetes who have diabetic kidney disease with HbA1c 6.5–10%, eGFR 30–90 mL/min/1.73 m2, and urine albumin-to-creatinine ratio of 500–5000 mg/g are the intended candidates.

Not a fit: People with non-diabetic kidney disease, those on dialysis or with a prior kidney transplant, medically unstable patients, or those recently hospitalized are unlikely to benefit or be eligible for this study.

Why it matters

Potential benefit: If successful, blocking ANGPTL3 could lower harmful lipids and slow progression of kidney damage in people with diabetic kidney disease.

How similar studies have performed: ANGPTL3 inhibition has produced strong lipid-lowering effects in prior studies and evinacumab is approved for rare lipid disorders, but its specific benefit for diabetic kidney disease remains largely unproven.

Eligibility criteria

Show full inclusion / exclusion criteria 
Key Inclusion Criteria:

1. Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management
2. Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening
3. eGFR 30 to 90 mL/min/1.73 m\^2 using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated Glomerular Filtration Rate using Creatinine and Cystatin C (CKD-EPI eGFRcr-cys) equation at screening
4. Albuminuria: Urine Albumin to Creatinine Ratio (UACR) of 500 to 5000 mg/g at screening

Key Exclusion Criteria:

1. Known medical history or clinical evidence indicative of non-diabetic renal disease
2. Renal disease that required treatment with systemic immunosuppressive therapy, or a history of dialysis or renal transplant
3. Medically unstable as assessed by the investigator
4. Hospitalization (ie, \>24 hours) within 30 days of the screening visit

NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply

Where this trial is running

Huntsville, Alabama and 46 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Diabetic Kidney DiseaseChronic Kidney DiseaseType 2 DiabetesLipid Management
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.